Dexpramipexole Dihydrochloride
Tier C — Watch / tradeDexpramipexole Dihydrochloride
Targets：DRDs, Free radicals
Indications (approved)：肺嗜酸粒细胞增多, Asthma, Chronic obstructive pulmonary disease, 高嗜酸性粒细胞综合征, Amyotrophic lateral sclerosis, 嗜酸粒细胞性哮喘, Fibromyalgia, Sinusitis
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| DEXP-012 | 106092-11-9 | (R)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine |
| DEXP-014 | 27514-08-5 | N-(4-oxocyclohexyl)acetamide |
| DEXP-015 | 104617-51-8 | N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)acetamide |
| DEXP-016 | 104617-49-4 | - |
| DEXP-017 | 106006-85-3 | (R)-N-(2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)propionamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| DEXP-001 | 4746-97-8 | 1,4-dioxaspiro[4.5]decan-8-one |
| DEXP-002 | 144810-01-5 | (1,4-dioxaspiro[4.5]dec-7-en-8-yloxy)trimethylsilane |
| DEXP-003 | 159015-33-5 | 5,7-dihydro-4H-spiro[benzo[d]thiazole-6,2'-[1,3]dioxolan]-2-amine |
| DEXP-004 | 113030-24-3 | 2-amino-4,5-dihydrobenzo[d]thiazol-6(7H)-one |
| DEXP-005 | 404892-23-5 | N-(6-oxo-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide |
| DEXP-006 | - | (R)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide |
| DEXP-007 | 1628866-44-3 | (S)-2-acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl benzoate |
| DEXP-008 | 1628866-45-4 | (S)-N-(6-hydroxy-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide |
| DEXP-009 | - | (S)-2-acetamido-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl 4-methylbenzenesulfonate |
| DEXP-010 | - | (R)-N-(6-azido-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide |
| DEXP-011 | 1400968-84-4 | (R)-N-(6-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide |
| DEXP-012 | 106092-11-9 | (R)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine |
| DEXP-013 | 599-91-7 | propyl 4-methylbenzenesulfonate |
Frequently asked questions
What are the approved indications of Dexpramipexole Dihydrochloride?
Approved indications include: 肺嗜酸粒细胞增多, Asthma, Chronic obstructive pulmonary disease, 高嗜酸性粒细胞综合征, Amyotrophic lateral sclerosis, 嗜酸粒细胞性哮喘, Fibromyalgia, Sinusitis.
When does the Dexpramipexole Dihydrochloride patent expire?
No public expiry year is available for Dexpramipexole Dihydrochloride yet; this page updates once verified.
How many synthesis routes are recorded for Dexpramipexole Dihydrochloride?
2 synthesis routes are recorded; the shortest is 5 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Dexpramipexole Dihydrochloride intermediates?
All intermediates in Dexpramipexole Dihydrochloride routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Dexpramipexole Dihydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-19